Skip to main content

Week in Review: CITIC Offers $3.6 Billion To Acquire China Biologic

CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products, one of China's top five plasma-based biopharmas (. The bid, which came at a 34% premium to the previous close, was unsolicited and non-binding.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.